Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.25B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.17M
Average 1.48M
Returns on capital
Mineralys Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.9%
avg 15.0%
ROIC
-26.4%
avg -137.7%
ROA
-23.4%
avg -94.9%
Analysis
ROA is currently the strongest return metric at -23.4% versus its period average of -94.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jon Congleton | President, Chief Executive Officer & Director | USD 1.11M | 63 | 528.62K | 0.80% |
James J. Ferguson FACC | Chief Medical Officer | USD 881.8K | 72 | — | — |
Adam Scott Levy | Chief Financial Officer & Secretary | USD 880.19K | 48 | 48.54K | 0.07% |
Brian Taylor Slingsby | Founder & Executive Director | USD 78K | 49 | 7.81M | 11.77% |
Eric J. Warren | Chief Commercial Officer | — | 54 | — | — |
Jeffrey A. Munsie | Chief Legal Officer | — | 49 | — | — |
Michael Tortorici | Senior Vice President of Translational Medicine | — | — | — | — |
Danielle Mahoney | Senior Vice President of Quality Assurance | — | — | — | — |
Robert McKean | Senior Vice President of CMC | — | — | — | — |
Jessica Ibbitson | Executive Vice President of Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$8.76M
Sells
56
$27.84M
Net Transaction Value
−$19.08M
Net selling
Most Active
Rodman David Malcom
37 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 30, 26Sep 30, 2026 | Congleton Jon Direct | Sell | $1.9M$1,909,665.00 |
| Sep 22, 26Sep 22, 2026 | Slingsby Brian Taylor Indirect | Sell | $3M$3,005,302.72 |
| Sep 21, 26Sep 21, 2026 | Warren Eric Direct | Sell | $209.1K$209,135.73 |
| Sep 15, 26Sep 15, 2026 | Karydas Daphne Direct | Sell | $85.7K$85,740.00 |
| Aug 21, 26Aug 21, 2026 | Warren Eric Direct | Sell | $193.2K$193,188.72 |
| Aug 10, 26Aug 10, 2026 | Rodman David Malcom Direct | Sell | $58.8K$58,785.30 |
| Jul 21, 26Jul 21, 2026 | Warren Eric Direct | Sell | $199.9K$199,885.09 |
| Jul 17, 26Jul 17, 2026 | Rodman David Malcom Direct | Sell | $11K$11,036.48 |
| Jul 15, 26Jul 15, 2026 | Rodman David Malcom Direct | Sell | $169K$168,954.51 |
| Jul 13, 26Jul 13, 2026 | Rodman David Malcom Direct | Sell | $387.7K$387,716.83 |
1–10 of 58
Summary
Insiders reported 2 buys worth $8.76M and 56 sells worth $27.84M over the last 12 months. That adds up to net selling of $19.08M. Rodman David Malcom was the most active insider with 37 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Mineralys Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about MLYS's management, answered from reported figures.
Who manages MLYS?
Mineralys Therapeutics, Inc. (MLYS) lists 10 active executives. The top listed executive is James J. Ferguson FACC, Chief Medical Officer.
Are MLYS insiders buying or selling?
Recent insider activity shows net selling of $4.85M.
Continue the stock analysis
Jump to another research area for this company.